INCREASED PLATELET DESTRUCTION
Caplacizumab, a bi-specific antibody that targets the A1 domain of von Willebrand factor and prevents vWF interaction with the platelet glycoprotein Ib-IX-V, can reduce the time to platelet count normalization and 30-day mortality.
CONGENITAL DISORDERS OF COAGULATION
While phase 3 clinical trials of gene therapy for hemophilia A and B have to date been restricted to patients 18 years of age and older, the results look extremely promising.
The International Society for Thrombosis and Haemostasis suggests use of specific direct-acting oral anticoagulants for cancer patients with a diagnosis of acute VTE, no drug-drug interactions, and a low risk of bleeding, but suggests use of low-molecular-weight heparin for those with a high risk of bleeding, including patients with luminal GI cancers with an intact primary tumor, and those at risk for bleeding from the genitourinary or GI tract.